louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03236714: Awareness and Compliance Among Health Professionals of the Preoperative Fasting Period
Official title: Awareness and Compliance Among Health Professionals of the Preoperative
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Preoperative Fasting
Lead sponsor: Tokat Gaziosmanpasa University
Sponsor class: OTHER
First posted: 2017-08-02
Enrollment: 300
Sex: ALL
Minimum age (years): 1
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients planning elective surgery according to the study

Brief summary: Preoperative fasting is mandatory for anesthetic induction. This period of fasting is probably greater due to delays in the surgical theater and changes in daily operation schedules.Investigators want to resarch between the prescribed and the actual preoperative fasting time.

Detailed description: Before surgery, the patients will be asked to liquid, solid fasting times.and whether information is given about the fasting period.In addition, the appropriateness of health personnel to new guidelines for preoperative fasting will be evaluated.At the end of the study, the desired duration of fasting, clinical practice and trends of health personnel will be investigated.

Eligibility criteria: Inclusion Criteria:

* Between 1 day and 80 years
* Elective surgery
* Oral fed
* American Society of Anesthesiologists score of 1 or 3

Exclusion Criteria:

* Intensive care patient
* Parenteral nutrition
* Emergency surgery

Primary outcomes:
measure: The patients' preoperative fasting period
timeFrame: one time in two months
measure: Training of health workers
timeFrame: one time in two months
Secondary outcomes:
Other outcomes:
Locations:
city: Tokat
country: Turkey
facility: Hakan Tapar
city: Tokat
country: Turkey
facility: Hakan Tapar
Study officials:
References:
Clinical trial NCT06352814: Activities-based Locomotor Training Program Versus Traditional Physical Therapy in Children With Cerebral Palsy
Official title: Impact of an Activities-based Locomotor Training Program Versus Traditional Physical Therapy in Children With Cerebral Palsy on Activity, Participation, and Neurophysiological Adaptations
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Cerebral Palsy
Keywords: cerebral palsy
children
activities-based locomotor training
neuroplasticity
Lead sponsor: Baylor University
Sponsor class: OTHER
First posted: 2024-04-08
Enrollment: 30
Sex: ALL
Minimum age (years): 2
Maximum age (years): 6
Standard ages: CHILD
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Community sample (central Texas)

Brief summary: The purpose of this study is to investigate the impact of an intensive activities-based locomotor training program as compared to traditional physical therapy on activity, participation, and central and peripheral neurophysiological adaptation in children with cerebral palsy.

Detailed description: Observational research will be performed to assess the change in outcome measure scores over time among participants after the AB-LT intervention. Outcome measures will be obtained 4 times, occurring every 3 weeks over a period of 9 weeks: pre-intervention, post-intervention, pre-traditional therapy, and post-traditional therapy. A washout period of 3 weeks will occur between the AB-LT intervention and traditional therapy.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of CP
* Between the ages of 2 to 12 years.
* Enrolled in a 3-week AB-LT program and/or participate in traditional physical therapy.

Exclusion Criteria:

* Surgery or botulinum toxin injections in the previous 6 months
* Uncontrolled epilepsy or cardiovascular disease.

Primary outcomes:
measure: Gross Motor Function Measure-66 (GMFM)
timeFrame: 9 weeks
measure: Pediatric Neuromuscular Recovery Scale (PedsNRS)
timeFrame: 9 weeks
measure: Pediatric Evaluation of Disability Inventory (PEDI-CAT)
timeFrame: 9 weeks
measure: Pediatric Quality of Life Inventory CP Module (PedsQL-CP)
timeFrame: 9 weeks
measure: Functional near-infrared spectroscopy
timeFrame: 9 weeks
measure: Electromyography
timeFrame: 9 weeks
measure: ActiGraph sensors
timeFrame: 9 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Waco
country: United States
facility: Baylor University
state: Texas
Study officials:
affiliation: Baylor University
name: Megan Flores
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06364514: PICNIC Study - PatIent Centered ANtIbiotic Courses in Children with Medical Complexity
Official title: PICNIC Study - PatIent Centered ANtIbiotic Courses in Children with Medical Complexity
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pneumonia
Lead sponsor: Boston Children's Hospital
Sponsor class: OTHER
First posted: 2024-04-15
Enrollment: 50
Sex: ALL
Minimum age (years): 2
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine if clinicians can safely reduce antibiotic exposure in children with medical complexity (CMC) who are diagnosed with pneumonia by implementing an intervention that bases total antibiotic duration on an individual's clinical stability.


Eligibility criteria: Inclusion Criteria:

* Admitted to the Complex Care Service at Boston Children's Hospital with a provider diagnosis of pneumonia
* Started on antibiotics by the provider team
* Ages 2-25 years old

Exclusion Criteria:

* Patients initially admitted to the intermediate care unit or ICU due to increased respiratory support needs

Primary outcomes:
measure: Proportion of eligible patients who consent to participate in the intervention
timeFrame: 48 hours
measure: Rate of persistent and worsening respiratory symptoms measured by patient's clinical status; the rate of emergency department revisit or hospital readmission within 1 week of antibiotic discontinuation
timeFrame: 1 week
Secondary outcomes:
measure: Median days of antibiotics received for patients in the intervention group as well as from historical control group
timeFrame: 30 days
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston Children's Hospital
state: Massachusetts
Study officials:
References:
Clinical trial NCT00862914: Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Naevi
Malignant Melanoma
Keywords: Skin
MicroRNA
miRNA
Dicer
Malignant Melanoma
Lead sponsor: Ruhr University of Bochum
Sponsor class: OTHER
First posted: 2009-03-17
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: dermatologic primary care clinic

Brief summary: MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study the researchers investigate the immunohistochemical distribution of Dicer in benign and dysplastic melanocytic naevi as well as in cutaneous malignant melanoma compared to intraindividual healthy control.


Eligibility criteria: Inclusion Criteria:

* Patients with benign melanocytic naevi, dysplastic melanocytic naevi and cutaneous malignant melanoma.

Exclusion Criteria:

* Patients under 18 years of age
* Patients with other forms of cancer in previous medical history
* Pregnancy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Bochum
country: Germany
facility: Department of Dermatology and Allergology, Ruhr-University Bochum
state: NRW
Study officials:
affiliation: Department of Dermatology and Allergology, Ruhr-University Bochum
name: Prof. Dr. Peter Altmeyer
role: PRINCIPAL_INVESTIGATOR
affiliation: Department of Dermatology and Allergology, Ruhr-University Bochum
name: PD Dr. Falk G. Bechara
role: STUDY_DIRECTOR
References:
citation: Sand M, Gambichler T, Sand D, Altmeyer P, Stuecker M, Bechara FG. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi. Eur J Dermatol. 2011 Jan-Feb;21(1):18-21. doi: 10.1684/ejd.2011.1210.
Clinical trial NCT00839514: Trichloroethylene (TCE) Exposure in an Industrial Population
Official title: Evaluation of Parkinson Disease Symptoms in Trichloroethylene Exposed Patients in an Industrial Population
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Parkinson's Disease
Keywords: Parkinson's disease
Trichloroethylene
Lead sponsor: University of Kentucky
Sponsor class: OTHER
First posted: 2009-02-09
Enrollment: 27
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Follow-up with individuals who previously particpated in the research study entitled "Survey of Selected Exposures and Neurologic Symptoms in an Industrial Population"

Brief summary: This study is to follow-up with workers from a local company that had exposure to TCE that may have symptoms of Parkinson's disease. We hope to learn more about TCE exposure and Parkinson's disease. Eligible participants will be those who participated in previous research study entitled "Survey of Selected Exposures and Neurologic Symptoms in an Industrial Population"


Eligibility criteria: Inclusion Criteria:

* Previous participant in the research study entitled "Survey of Selected Exposures and Neurologic Symptoms in an Industrial Population"

Exclusion Criteria:

* Not a participant in the research study entitled "Survey of Selected Exposures and Neurologic Symptoms in an Industrial Population"

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Lexington
country: United States
facility: University of Kentucky
state: Kentucky
Study officials:
affiliation: University of Kentucky
name: John T Slevin, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Gash DM, Rutland K, Hudson NL, Sullivan PG, Bing G, Cass WA, Pandya JD, Liu M, Choi DY, Hunter RL, Gerhardt GA, Smith CD, Slevin JT, Prince TS. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol. 2008 Feb;63(2):184-92. doi: 10.1002/ana.21288.
Clinical trial NCT02695914: Influence of Compound Qingre Granule on the Inflammatory Markers in Patient of FUO With Excess-heat Syndrome
Official title: Inflammatory Markers in Patient of FUO With Excess-heat Syndrome and the Influence of Compound Qingre Granule on the Inflammatory Markers
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Fever of Unknown Origin
Keywords: Inflammatory markers
Lead sponsor: Beijing Friendship Hospital
Sponsor class: OTHER
First posted: 2016-03-01
Enrollment: 80
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patient of fever of unknown origin with excess-heat syndrome

Brief summary: The purpose of this study is to observe inflammatory markers like TNF (tumor necrosis factor), IL-1 (interleukin-1), IL-6 (interleukin-6),TREM-1 (triggering receptor expressed on myeloid cells-1), etc, in patient of FUO with excess-heat syndrome and the influence of Compound Qingre Granule on the inflammatory markers.

Detailed description: All the cases will be provided by the Infectious Diseases Department of Beijing Friendship Hospital.Each patient should sign informed consent. Assessing the accuracy, completeness, or representativeness of registry data by comparing the data to medical records. After collecting, sorting and entering the data, reducing the missing value, and then checking into the database.

The stochastic indicator method will be used to simple random sampling, to ensure the probabilities of each individuals be given Chinese medicine intervention are equal.Operations must be standard to reduce errors.

Quality assurance plan: Patient of fever within two weeks, or whose temperature is below 38.5 degree centigrade will be excluded. The registration form includes the following parts: Name, sex, age, address, phone number, admission time, primary diagnoses and levels of Inflammatory markers.

Data will be analyzed using the SPSS17.0 (Statistical Product and Service Solutions 17.0) statistical software. Difference of measurement data will be compared with analysis of variance,and difference of enumeration data will be compared with rank-sum test.P\<0.05 has statistical significance.

Eligibility criteria: Inclusion Criteria:

* Patient of fever of unknown origin (FUO).

Exclusion Criteria:

* Patient of fever within two weeks, or whose temperature is below 38.5 degree centigrade.

Primary outcomes:
measure: Inflammatory marker (TREM-1) in patient of FUO
timeFrame: 7th day
Secondary outcomes:
measure: Inflammatory marker (TNF) in patient of FUO
timeFrame: 7th day
measure: Inflammatory marker (IL-1) in patient of FUO
timeFrame: 7th day
measure: Inflammatory marker (IL-6) in patient of FUO
timeFrame: 7th day
Other outcomes:
Locations:
Study officials:
affiliation: Beijing Friendship Hospital
name: Chao Wang, Doctor
role: STUDY_DIRECTOR
References:
Clinical trial NCT06252714: Impact of Defecation Posture on Ease of Bowel Movements in Patients With a Rectocele
Official title: Impact of Defecation Posture on Ease of Bowel Movements in Patients With a Rectocele.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pelvic Organ Prolapse
Rectocele
Bowel Dysfunction
Keywords: defecation posture modification device
defecation posture
Lead sponsor: TriHealth Inc.
Sponsor class: OTHER
First posted: 2024-02-12
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study aims to determine if defecation posture, when using a defecation posture modification device (DPMD), will improve ease of bowel movements in patients with pelvic organ prolapse, specifically rectoceles.


Eligibility criteria: Inclusion Criteria:

* Patients with pelvic organ prolapse, including a rectocele (posterior compartment measurements to Stage 2 or greater) that endorse bowel dysfunction, based on our office standard screening questionnaires

Exclusion Criteria:

* Anyone currently using a defecation posture modification device Unwillingness or unable to participate in the study Planned travel, inability to use device during the study period Patient preparing to undergo pelvic reconstructive surgery prior to the end of the study period Presence of ileostomy/colostomy Bowel disease such as Crohn's disease or Ulcerative Colitis Daily opiate use Wheelchair bound If device may pose fall or safety hazard risk to patient, such as need for walker or cane for ambulation.

Patients weighing over 250 lbs, per manufacturer guidelines for the device Inability to understand English Pregnant women

Primary outcomes:
measure: Straining with bowel movements
timeFrame: 2 weeks
Secondary outcomes:
measure: Colorectal-Anal Distress Inventory 8
timeFrame: 2 weeks
measure: Consistency of stool
timeFrame: 2 weeks
measure: Use of laxative medication
timeFrame: 2 weeks
measure: Ease of device use
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: Cincinnati Urogynecology Associates
state: Ohio
city: Cincinnati
country: United States
facility: Good Samaritan Hospital
state: Ohio
city: Cincinnati
country: United States
facility: Bethesda North Hospital
state: Ohio
Study officials:
References:
Clinical trial NCT06949514: Guided Imagery in Hospitalized Pregnant Women
Official title: The Effect of Guided Imagery on Anxiety, Depression, and Sleep in Hospitalized Pregnant Women
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Pregnancy
Lead sponsor: Ankara University
Sponsor class: OTHER
First posted: 2025-04-29
Enrollment: 50
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The study will be carried out in two different groups. Participants will be approached after being hospitalized for at least 24 hours. After the pregnant women are evaluated in terms of eligibility criteria for the research, the pregnant women who are eligible will be informed about the research and written informed consent will be obtained from the pregnant women who accept. The random distribution of pregnant women to the study groups will be carried out random.


Eligibility criteria: Inclusion Criteria:

* Being 18 years of age or older
* Having no difficulties in understanding and speaking Turkish
* Being hospitalized for at least 24 hours
* Being in the second trimester of pregnancy (14-28 weeks)
* Having a medically stable condition
* Experiencing sleep disturbances
* Voluntarily agreeing to take part in the study

Exclusion Criteria:

* Having a hearing impairment
* Having ongoing severe vaginal bleeding
* Having a diagnosed psychiatric disorder and/or using psychiatric medication
* Having uncontrolled hypertension
* Presence of intrauterine fetal demise
* Premature rupture of membranes (PROM)
* Being in preterm labor

Primary outcomes:
measure: Change in anxiety
timeFrame: at the beginning of the study, 3 days later
measure: Change in Depression
timeFrame: at the beginning of the study, 3 days later
measure: Change in Sleep Quality
timeFrame: at the beginning of the study, 3 days later
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00800514: Amantadine and Temporal Discrimination in Patients With Traumatic Brain Injury (TBI)
Official title: Amantadine and Temporal Discrimination in Patients With Traumatic Brain Injury
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Traumatic Brain Injury
Keywords: perception of time, traumatic brain injury, amantadine
Lead sponsor: Wake Forest University Health Sciences
Sponsor class: OTHER
First posted: 2008-12-02
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The study will explore the neurocognitive effect of four weeks of treatment with amantadine versus placebo in patients with traumatic brain injury using the Interval Bisection Timing Task. Approximately 16 individuals with traumatic brain injury are expected to participate in this study. Subject participation is expected to last up to 8 weeks with 16 study visits.


Eligibility criteria: Inclusion Criteria:

* Age 18 to 55 inclusive. History of post-MVA close head TBI. Female subjects must use an acceptable method of contraception during entire study. Acceptable methods of contraception are: history of surgical sterility, postmenopausal status, hormonal contraceptives, or accepted barrier devices (i.e., male/female condom, diaphragm, cervical cap, intrauterine device).

Exclusion Criteria:

* Current or past history of major psychiatric disorder (schizophrenia, bipolar disorder, major depressive disorder)
* Substance use disorder
* Current or past history of serious chronic medical condition (pulmonary (lung), cardiovascular (heart), hepato-renal (liver-kidney) disease, diabetes)
* Seizures
* Smoking one or more packs of cigarettes per day
* If you are pregnant or breastfeeding, or plan to become pregnant during the study

Primary outcomes:
measure: The primary outcome measure is the Interval Bisection Timing Task.
timeFrame: 12 -16 months
Secondary outcomes:
measure: The secondary efficacy measure is the Barrett Impulsiveness Scale (BIS-11).
timeFrame: 12-16 moths
Other outcomes:
Locations:
city: Charlotte
country: United States
facility: CHS-Behavioral Health Research
state: North Carolina
Study officials:
affiliation: Carolians HealthCare System
name: Oleg V. Tcheremissine, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00100295: Herbal Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
Official title: Controlled Trial of an Herbal Treatment for Juvenile Attention Deficit Hyperactivity Disorder
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Attention Deficit Hyperactivity Disorder
Keywords: Adolescent
Child
Phytotherapy
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH)
Sponsor class: NIH
First posted: 2004-12-29
Enrollment: 59
Sex: ALL
Minimum age (years): 6
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and effectiveness of an herbal product for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents.

Detailed description: ADHD is a common childhood disorder associated with concentration problems and disruptive behavior. Evidence suggests that herbal remedies may be as effective as standard drug therapies in treating ADHD symptoms. This study will determine the safety and efficacy of an herbal treatment in children and adolescents with ADHD.

This study will last 9 weeks. Participants will be randomly assigned to receive either an herbal product or placebo three times a day for the duration of the study. Participants will come in for weekly study visits at which their ADHD symptoms and any side effects will be assessed by self-report rating scales.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of ADHD
* Score of greater than 1.5 standard deviation above the age and gender norms on the ADHD-IV rating scale
* Parents and children can understand English
* Parents and children willing to attend all study visits
* Able to swallow study medication
* Willing to use acceptable methods of contraception

Exclusion Criteria:

* Severe depression
* History of bipolar disorder, psychosis, severe conduct disorder, or other serious medical conditions
* Use of medications that may interact with the herbal product
* Current use of medications to treat ADHD
* Previous use of Hypericum
* Pregnancy

Primary outcomes:
measure: ADHD-IV rating scale
timeFrame: Difference between baseline and end of study
measure: side effects scale
timeFrame: Freqency of events during entire study
Secondary outcomes:
measure: Child Behavior Checklist, Youth Self Report Form
timeFrame: Baseline and end of study
Other outcomes:
Locations:
city: Kenmore
country: United States
facility: Bastyr University
state: Washington
Study officials:
affiliation: Bastyr University
name: Wendy Weber, ND, MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Weber W, Vander Stoep A, McCarty RL, Weiss NS, Biederman J, McClellan J. Hypericum perforatum (St John's wort) for attention-deficit/hyperactivity disorder in children and adolescents: a randomized controlled trial. JAMA. 2008 Jun 11;299(22):2633-41. doi: 10.1001/jama.299.22.2633.